Citrix Systems CTXS reported third-quarter 2020 non-GAAP earnings of $1.38 per share, beating the Zacks Consensus Estimate by 12.2%. However, the bottom line declined 9.2% on a year-over-year basis.
Revenues of $767.17 million surpassed the Zacks Consensus Estimate by 1.24%. The top line improved 5% on a year-over-year basis. Robust adoption of the company’s offerings enabling secure remote work amid coronavirus crisis-induced work-from-home wave was a key catalyst.
Product and license revenues (11% of total revenues) declined 33% year over year to $87 million.
Support and services revenues (54%) decreased 6% on a year-over-year basis to $417 million.
Subscription revenues (34%) surged 56% from the year-ago figure to $263 million.
During the quarter under review, SaaS revenues were $138 million (52% of total subscription revenues), up 37% year over year. Notably, SaaS revenues account for significant part of subscription transition. Other subscription revenues in the reported quarter totaled $125 million, soaring 111% year over year.
Citrix Systems, Inc. Price, Consensus and EPS Surprise
Citrix Systems, Inc. price-consensus-eps-surprise-chart | Citrix Systems, Inc. Quote
Revenues as per Product Group
Workspace revenues (75% of total revenues) increased 12% year over year to $573 million courtesy of higher adoption of SaaS-bases subscription solutions. Workspace subscription revenues improved 26% year over year, and contributed 35% to the figure. Approximately 80% of Workspace product bookings were subscription based. Sharp increase in Workspace deployments benefited growth as employees were compelled to work remotely in the wake of the coronavirus pandemic, which called for secure remote work infrastructure.
However, Networking revenues (22%) declined 12% from the year-ago period to $166 million. Networking subscription revenues soared 136% from the prior-year figure. Networking software revenues contributed 48% to the figure. Approximately 66% of Networking product bookings were subscription based. The company anticipates shift toward software-based solutions from traditional hardware to weigh on Networking revenues in the days ahead. The company will report Networking product grouping to App Delivery and Security beginning fourth-quarter 2020.
Professional Services revenues (4%) declined 13% on a year-over-year basis to $28 million. As business shifts toward subscription solutions, Professional services revenues are anticipated to decline over time.
Customer Wise Revenues
Revenues from SSP customers amounted to $22 million (3% of total revenues) during the reported quarter, down 44% year over year. Revenues from non-SSP customers (97% of total revenues) improved 7% year over year to $746 million.
Revenues in the Americas (54% of total revenues) were $414 million, down 1% on a year-over-year basis. Meanwhile, revenues in Europe, Middle East and Africa or EMEA (36% of total revenues) advanced 17% from the year-ago quarter to $276 million. Revenues in Asia-Pacific and Japan or APJ (10% of total revenues) declined 3% year over year to $76 million.
Total operating expenses increased 3.3% year over year to $511.6 million. As a percentage of revenues, the figure contracted 90 basis points (bps) to 66.7%.
Non-GAAP operating margin was reported at 29%, which contracted 200 bps sequentially.
Balance Sheet & Cash Flow
As of Sep 30, 2020, Citrix had cash and cash equivalents and short-term investments of $938 million compared with $880 million as of Jun 30, 2020. As of Sep 30, 2020, long-term debt at the end of the quarter came in at $1.73 billion, flat sequentially.
Cash flow from operations was reported at $112 million, compared with $419 million in the prior quarter.
The company has $714 million remaining in share repurchase authorization.
The company paid out quarterly dividends worth $43 million.
Notably, Citrix’s board of directors approved a cash dividend of 35 cents per share, payable on Dec 22, to shareholders as on Dec 8.
For fourth-quarter 2020, Citrix anticipates revenues between $775 million and $785 million. The Zacks Consensus Estimate for revenues is pegged at $779.1 million.
Moreover, non-GAAP earnings are expected in the range of $1.25 to $1.35 per share. The Zacks Consensus Estimate for earnings is pegged at $1.30 per share.
Tweaks 2020 Revenue Outlook
For full-year 2020, Citrix now expects revenues between $3.20 billion and $3.21 billion, compared with the earlier guided range of $3.18-$3.21 billion. The Zacks Consensus Estimate for revenues is pegged at $3.20 billion.
Moreover, non-GAAP earnings are now expected between $5.89 and $5.99, compared with the previously guided range of $5.65-$5.85 per share. The Zacks Consensus Estimate for earnings is pegged at $5.79 per share.
Management now anticipates non-GAAP operating margin to be near 29.5%. Earlier, the company had guided non-GAAP operating margin in the range of 28-29%.
Preliminary 2021 View
For 2021, Citrix anticipates revenues to grow 4% on a year-over-year basis.
Moreover, non-GAAP earnings are expected between $6.20 and $6.40 per share. The Zacks Consensus Estimate for earnings is pegged at $6.18 per share.
Zacks Rank & Stocks to Consider
Citrix currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Avnet AVT, CDW Corporation CDW and Advanced Micro Devices AMD. While Avnet and CDW sport a Zacks Rank #1 (Strong Buy) at present, AMD carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Avnet, CDW and AMD are scheduled to report quarterly results on Oct 28, Nov 2, and Oct 27, respectively.
Long-term earnings growth rate of Avnet, CDW and AMD is pegged at 17.88%, 13.1% and 45.82%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Avnet, Inc. (AVT) : Free Stock Analysis Report
Citrix Systems, Inc. (CTXS) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
CDW Corporation (CDW) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research